Angel News

Angel News

Back to Homepage

14th January 2019

Chronomics secures £1.12 million seed funding

Chronomics, a pioneering company in health-tech innovation, has just launched the world’s first consumer epigenetic testing kit. Chronomics has successfully secured more than £1.12 million in funding, including significant investment from venture capital firm Anthemis, and follow on funding from SOSV, one of the world’s most active early stage biotech investors.

The four founders of Chronomics are leading in their respective fields. Dr Tom Stubbs and Daniel Herranz worked at the forefront of epigenetics research at the University of Cambridge, where they collaborated with Dr Toby Call, a Bioenergy and Industrial Biotechnology expert, to define the first models. The team brought on board Charles Ball whose extensive commercial experience has helped to explain the intricacies of epigenetic science to the public.


Register now to read full story

In order to read the full story we need you to register with us, please click the link below:

Register Now

Add a comment:




Enter the characters in the image shown:

Back to Homepage